Dr John Byon has been named as senior vice president of clinical development, bringing a wealth of experience and expertise to that role.
Dr Byon’s appointment comes just weeks after Imugene named Dr Bradley Glover as the company’s new chief operating officer.
Company Information
Company
Imugene
Location
Sydney, New South Wales, Australia
About
Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. onCARlytics (CF33-CD19) is a novel and effective combination immunotherapy utilising the CF33 oncolytic virus to deliver and present CD19 antigen on the surface of cancer cells promoting CD19 CAR T cell anti-tumour responses against solid tumours.
Fundz sees it the moment Imugene changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
SydneyBiotechnologyHealth CareMedicalTherapeutics